Recent updates in human leukocyte antigen B27–associated uveitis Authors: Shishir Narain, Priyanka Gupta, Richa Pyare, Daraius Shroff, Prasan D Rath Published: 2026 ABSTRACT There has been progressive understanding in etiopathogenesis, clinical presentation, and effective treatment of anterior uveitis (AU) over the years. Sudden onset, symptomatic acute anterior uveitis (AAU) in a young adult, often male, classically arouses suspicion for human leukocyte antigen (HLA) B27-related uveitis. While the ocular presentation is frequently the earliest manifestation, its systemic counterparts within the spectrum, viz., spondyloarthropathies (SpA), including ankylosing spondylitis (AS), reactive arthritis (RA), psoriatic arthritis (PA), and inflammatory bowel disease–associated inflammation, pose greater diagnostic and therapeutic challenges for rheumatologists and internists. This places the ophthalmologist in a uniquely advantageous yet responsible position in initiating etiologic evaluation and facilitating early systemic recognition. Rapid advances in immunology and molecular medicine have significantly expanded the diagnostic and therapeutic landscape of HLA B27–related disease. Emerging insights implicating the gut microbiome, autoinflammatory mechanisms, and innate immune dysregulation have reshaped traditional concepts of pathogenesis. Concurrently, an improved understanding of cytokine networks and immune signaling pathways has led to the development of targeted biologic and synthetic disease-modifying therapies. Given the dynamic, multisystem nature of HLA B27–associated disease and its variable organ involvement, optimal management necessitates close multidisciplinary collaboration among ophthalmologists, rheumatologists, gastroenterologists, and internists. This article briefly explores the evolving concepts of the complex enigma of the HLA B27 molecule and the basis for recent trends in its understanding at the cellular, molecular, biochemical, and clinical levels. Anterior uveitis (AU) is the most common form of uveitis,[1] and approximately 50% of all patients with acute anterior uveitis (AAU) are human leukocyte antigen B27 (HLA B27) positive.[2] The association between the HLA B27 gene and AAU was first described in 1973 by Schlosstein et al.[3] and Brewerton et al.[4] Since then, it has been shown to be associated with a diverse spectrum of phenotypic diseases, including AAU, ankylosing spondylitis (AS), reactive arthritis (RA), inflammatory bowel disease–associated arthritis (IBD), and psoriatic arthritis (PA). Despite being the focus of much clinical and experimental research, the precise pathogenesis of HLA B27 associated with AAU and spondyloarthropathies (SpA) remains an enigma.[567] Emerging evidence implicates interactions with the gut microbiome and a complex interplay between innate and adaptive immunity. Clinically, topical and systemic corticosteroids remain the cornerstone of therapy for management of acute episodes of AU, and a whole range of conventional disease-modifying anti-rheumatic drugs (DMARDs), biologics, and targeted synthetic DMARDs (tsDMARDs) like Janus kinase inhibitors (JAKi) have been used to manage severe, chronic, or relapsing disease.[89] Methods A focused narrative review of the literature was performed to examine current concepts and recent advances in HLA B27–associated uveitis. A PubMed/MEDLINE search was conducted using relevant Medical Subject Headings (MeSH) terms and keywords, including HLA B27, AAU, SpA, AS, RA, PA, inflammatory bowel disease, gut microbiome, autoinflammation, cytokines, and biologic therapies. Articles published in English were reviewed, with emphasis on recent literature, whereas key earlier studies were included where conceptually relevant. Additional articles were identified through manual screening of reference lists of selected publications (snowballing). The literature was qualitatively synthesized with a focus on clinical relevance, immunopathogenesis, systemic associations, and implications for multidisciplinary management. The Basis of Inflammation The HLA B27 molecule is a complex 3-dimensional structure belonging to the HLA class I family of genes. Its role in the immune system is to present peptide antigens to CD8 T cells in addition to T-cell receptors (TCR).[10] Given this association with antigen presentation, HLA B27 SpA are classically considered diseases of adaptive immunity or auto-immune conditions. The classical hypothesis for disease pathogenesis is the arthrogenic peptide theory, based on cross-reactivity between the natural ligands of HLA B27 and bacterial peptides.[1011] However, there is more recent data suggesting a role of a disordered innate immune response in the disease pathogenesis. HLA B27 misfolding hypothesis posits that HLA B27 misfolding within the endoplasmic reticulum (E) leads to activation of ER stress signaling pathways and further cytokine dysregulation.[12] Another theory suggests that HLA B27 molecules homodimerize on the cell surface, leading to activation of innate immunity.[13] Results of genome-wide association studies (GWAS) in AS, PA, and AU suggest a polygenic nature of these diseases. Besides HLA B27, one of the gene variants most consistently associated with inflammatory diseases is ERAP1.[14] ERAP1 helps in peptide trimming before Major Histocompatibility Complex (MHC) loading, and in proper folding of HLA B27, and pathogenic ERAP1 variants can potentially lead to improper antigen presentation or HLA B27 misfolding, contributing to both auto-immune and autoinflammatory pathways of inflammation.[15] Other associated pathogenic variants include TRAF3IP2, PTPN22, and RUNX3, among others.[1516] In the absence of a clear-cut mechanism of inflammation, HLA B27 uveitis stands at the crossroads of autoimmunity and autoinflammation. Another area of active research includes exploring the relation between the gut microbiome and HLA B27 inflammation. Dysbiosis is theorized to lead to impaired gut barrier function, disrupted intestinal immune tolerance, and ocular immune privilege.[1718] Clinical Presentation of AAU In a large cohort study of more than 2000 cases with known AS,[19] 23.5% of patients had at least one episode of AAU (mean age: 51 years, male-to-female ratio: 2:1). Clinically, AAU classically presents with unilateral acute onset of blurred vision, severe redness, ocular pain, and photophobia, with a tendency for alternating eye involvement; simultaneous bilateral episodes are uncommon. HLA B27 AU and idiopathic AAU are both common and clinically present similarly, with no protean pathognomonic clinical symptom or sign to label either entity unequivocally. However, careful analysis shows HLA B27 AU to often be a more acute and severe condition as compared with idiopathic AU, with a younger age of onset, male predominance, more extensive fibrinous AC exudates, and hypopyon with alternating unilateral attacks, often associated with back pain or SpA and psoriasis or associated family history of HLA B27-related entities.[20] Intense prostaglandin (PG) release within the AC may result in secondary posterior segment manifestations, especially cystoid macular edema (CME) and optic disc edema.[21] Recently, pigmentation of the central anterior lens capsule (PioLe) was reported as a presenting feature, and along with unilaterality, hypopyon, and intraocular pressure (IOP) <21 mm, the presence of PioLe was highly suggestive of HLA B27 AAU.[22] Although HLA B27-related uveitis is primarily an anterior segment disease, recent reports indicate that intermediate uveitis and peripheral retinal vascular involvement may be more common than previously appreciated.[23] Severe or recurrent attacks may lead to structural complications, including cataract, glaucoma, and CME, with some patients progressing to chronic AU. AAU is marked by a high recurrence rate, averaging 0.6–3.3 episodes per patient per year, with individual attacks typically lasting 4–6 weeks.[2425] Role of Ophthalmologist AAU represents the most frequent extra-articular manifestation of SpA, occurring in over 20% of patients. Importantly, up to 40% patients with AAU have as yet undiagnosed underlying systemic disease, placing the ophthalmologist in a pivotal role for early recognition and referral.[26] While a typical episode of AAU in a young adult immediately raises suspicion of HLA B27–associated uveitis, other systemic phenotypes such as AS, PA, RA, and IBD-related disease may be clinically occult, highlighting both the opportunity and responsibility for appropriate systemic work-up. The Dublin Uveitis Evaluation Tool (DUET) was developed as a simple, ophthalmologist-friendly screening algorithm for patients presenting with AAU.[27] Patients without a prior diagnosis of SpA were screened for the presence of inflammatory back pain with onset before 45 years of age and duration greater than three months, or peripheral joint pain requiring general practitioner consultation, prompting HLA B27 testing. Patients testing positive or having psoriasis were given a rheumatology referral; those testing negative were given an information handout. In this study, the DUET algorithm demonstrated excellent diagnostic performance, and approximately 40% of idiopathic AAU cases were detected to have undiagnosed SpA. Techniques of Testing for HLA B27 Laboratory investigation for HLA B27 currently uses two techniques, viz., polymerase chain reaction (PCR) to detect the presence of the DNA of the gene itself and flow cytometry (FC) to detect protein on WBCs. FC has been commonly used as it is easily available, fast, and cost-effective, but the PCR method offers higher accuracy in identifying the specific gene and is the preferred method currently. A recent study concluded FC demonstrated noteworthy sensitivity and satisfactory accuracy in HLA B27 detection, but with a reduced specificity when contrasted with PCR, and given its cost-effectiveness and streamlined operation relative to PCR, FC remains a pragmatic option for preliminary screening in clinical practice, especially in low-income regions.[28] Previously available methods were serological testing to detect the surface antigen and microarray technology (molecular technique) for large-scale screenings or specific subtype analysis, but have lower precision than both PCR and FC. Attempts are made to develop a rapid diagnostic tool that is highly specific and sensitive but inexpensive, less time-consuming, and less labor-intensive. Recently, a novel test, viz., BASIC, was developed by combining the isothermal amplification method with the CRISPR/Cas12a signal output tool to achieve a fluorescence signal output.[29] Treatment – Conventional and Newer Therapies Presently, first-line therapy for HLA B27 AAU is intensive topical corticosteroids and cycloplegic mydriatics. They remain the mainstay of treatment for single or recurrent episodes of unilateral or bilateral AAU flares, primarily as the AC is readily accessible to topical therapy. Atropine 1% provides the most effective cycloplegia; however, prolonged use may result in posterior synechiae in a fixed dilated position. Shorter-acting agents such as homatropine 2% may be preferred to maintain pupil mobility. Cyclopentolate has been reported to have chemotactic properties and is relatively contraindicated. Topical corticosteroids, preferably prednisolone acetate 1%, are initiated at frequent dosing (every 1–2 hours; 8–12 times daily) and gradually tapered over 6–8 weeks as AC reaction subsides. Up to 30% patients develop elevated IOP due to steroid responsiveness, necessitating the addition of antiglaucoma agents. In severe or recurrent cases of AAU, additional systemic NSAIDs, corticosteroids, or immunomodulatory therapy (IMT) may be required. In patients with vision-threatening uveitis due to CME, the The PeriOcular vs. INTravitreal corticosteroids for uveitic macular edema (POINT) Trial POINT trial found periocular corticosteroid injections to be safe and effective, both as monotherapy or as adjunctive treatment.[3031] One of the challenges in the treatment of HLA B27 uveitis is the prevention of recurrences. Although a few studies have shown a role for nonsteroidal anti-inflammatory drugs (NSAID) s and DMARDs, including sulfasalazine, in preventing recurrences of AAU in HLA B27-positive patients,[3233] most patients with recurrent disease will require IMT. The systemic immunosuppressive treatment for eye diseases (SITE) study showed equivalent efficacy of methotrexate (MTX) and mycophenolate mofetil (MMF), but a faster onset of action for MMF.[34] The first-line antimetabolites as steroid-sparing treatment (FAST) research group has also shown comparable efficacy for MTX and MMF as steroid-sparing agents in recurrent uveitis.[35] Beyond conventional IMT, the introduction of biologics, especially Tumor Necrosis Factor (TNF) inhibitors (TNFi), has dramatically improved outcomes in these patients. Adalimumab and golimumab have been shown to reduce recurrences and improve outcomes in both SpA and uveitis.[3637] On the other hand, etanercept, another TNFi, although very effective in improving outcomes in the spine and joints, has been implicated in paradoxical induction of uveitis in AS patients.[3839] In patients with recurrent disease that is recalcitrant to TNFi, the options include interleukin-17 blockers (secukinumab) and interleukin 12/23 blockers (ustekinumab), which are also licensed for the treatment of SpA, with different proven efficacy in preventing and treating AAU.[40] A new paradigm shift in the management of HLA B27-related inflammation has been brought about by the introduction of JAKi, classified as ts DMARDs (tsDMARDs). These have a very broad range of action as they act by inhibiting multiple intracellular cytokine signaling pathways.[9] JAKi have demonstrated efficacy in axial SpA,[4142] but their defining role in uveitis still remains under investigation.[43] In summary, local and systemic corticosteroids remain the cornerstone of management for acute episodes of AU with HLA B27. Recurrent or recalcitrant chronic disease where steroids cannot be tapered to below <7.5 mg/day or <2 drops/day or need to be restarted within a month of stopping treatment needs to be managed with IMT. First-line IMTs include methotrexate and mycophenolate mofetil. Step-wise therapy escalation is required in case of disease resistance to these drugs. Most frequently used second-line agents presently are TNFi, specifically adalimumab and golimumab. Beyond TNFi, JAKi represents the next line of management in HLA B27-related recurrent or chronic inflammation. Unanswered Questions The prevalence of HLA B27 varies from 2–8% across populations and is strongly associated with SpA.[44] Why only a subset of HLA B27-positive individuals develop manifest disease remains unclear. The precise pathogenesis of AAU and SpA with the HLA B27 gene and the role of microbial triggers is incompletely understood. Intriguingly, a single genotype gives diverse phenotypes, including AAU, AS, RA, PA, and IBD-associated arthritis, highlighting important gaps in mechanistic understanding. Further defining the cellular and molecular drivers of gene activation is essential for the development of newer targeted and safer therapeutic strategies. Conclusion HLA B27-related uveitis is a deceptively simple disease with much work yet to be done to elucidate its pathogenesis. The management of HLA B27 AU in acute cases is standardized, but managing recurrent disease remains challenging. The path forward in management will be illuminated by further breakthroughs in the molecular mechanisms responsible for inducing inflammation and especially recurrences. Conflicts of interest There are no conflicts of interest.